母体西罗莫司治疗胎儿心脏横纹肌瘤
本文综述胎儿心脏横纹肌瘤的病理生理及产前治疗新选择,并报告一例TSC2突变胎儿因横纹肌瘤导致显著血流动力学障碍而接受母体西罗莫司宫内治疗。西罗莫司从孕28周用至36周,心脏状态改善,但期间出现宫内生长受限;新生儿期横纹肌瘤及心功能稳定,6月龄发育里程碑适当。
要点
- 母体西罗莫司从孕28周用至36周,胎儿心脏状态改善。
- 治疗期间出现宫内生长受限。
- 新生儿期未重启西罗莫司,横纹肌瘤及心功能稳定。
核心结论
- 对于产前发生的大型梗阻性横纹肌瘤伴心脏受损的咨询病例,可考虑宫内西罗莫司治疗。
研究设计与样本
- 本文为病例报告并综述胎儿心脏横纹肌瘤的病理生理及产前治疗选择。
- 病例为一名因横纹肌瘤导致显著血流动力学障碍的胎儿,羊膜腔穿刺遗传学检查证实TSC2突变。
主要发现
- 西罗莫司从孕28周开始用至孕36周,胎儿心脏状态改善。
- 治疗期间出现宫内生长受限。
- 出生后未重新启用西罗莫司,婴儿横纹肌瘤及心脏功能保持稳定。
- 脑MRI显示散在皮质结节和室管膜下结节,婴儿未出现癫痫样活动。
- 6月龄时婴儿达到适当的发育里程碑。
关键数值与推荐
- 西罗莫司以10 mg负荷剂量起始,滴定至母体谷浓度目标10至15 ng/dL。
- 采用斑点追踪超声心动图在治疗前后评估胎儿心脏功能。
- 产前超声监测胎儿生长,出生后通过临床监测、超声心动图和脑MRI随访至6月龄。
临床怎么用
- 在咨询产前大型梗阻性横纹肌瘤伴心脏受损的病例时,可考虑宫内西罗莫司治疗。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To review the pathophysiology of rhabdomyomas and the emerging option of prenatal treatment of fetal cardiac rhabdomyomas. METHODS: We present a case of fetal rhabdomyomas causing significant hemodynamic compromise that received in utero treatment of maternal sirolimus. Genetic amniocentesis confirmed a TSC2 mutation. A treatment program was initiated with a 10-mg loading dose titrated to a goal maternal trough of 10 to 15 ng/dL. In order to follow fetal cardiac function, a sophisticated method of speckle tracking echocardiography was used before and after treatment. Obstetric ultrasound was used to monitor fetal growth, and clinical surveillance, echocardiography, and brain MRI were used to monitor postnatal growth and development through 6 months of neonatal life. RESULTS: Sirolimus was initiated from 28 to 36 weeks of gestation with improvement of cardiac status. During this period, intrauterine growth restriction developed. Postnatally, the infant has had stable rhabdomyomas and cardiac function without reinitiating sirolimus. Brain MRI demonstrated scattered cortical tubers and subependymal nodules, and the infant has not had seizure-like activity. At 6 months of age, the infant has achieved appropriate developmental milestones. CONCLUSION: In counseling cases of prenatal onset large obstructing rhabdomyomas and cardiac compromise, in utero sirolimus treatment can be considered.
引用
- Pluym ID, Sklansky M, Wu JY, et al. Fetal cardiac rhabdomyomas treated with maternal sirolimus. Prenat Diagn. 2020. PMID: 31742705. doi:10.1002/pd.5613
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。